These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19241338)

  • 21. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma.
    Choo R; Klotz L; Deboer G; Danjoux C; Morton GC
    BJU Int; 2004 Aug; 94(3):295-8. PubMed ID: 15291854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
    Schmid HP
    Cancer Surv; 1995; 23():157-67. PubMed ID: 7542562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling prostate specific antigen kinetics in patients on active surveillance.
    Zhang L; Loblaw A; Klotz L
    J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations.
    Ross PL; Mahmud S; Stephenson AJ; Souhami L; Tanguay S; Aprikian AG
    Urology; 2004 Aug; 64(2):323-8. PubMed ID: 15302488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
    Abouassaly R; Lane BR; Jones JS
    Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
    Perlmutter MA; Lepor H
    Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
    Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
    Klotz L
    Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1357-63. PubMed ID: 19395198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple graphic method for estimation of prostate-specific antigen doubling time.
    Sengupta S; Slezak JM; Blute ML; Bergstralh EJ
    Urology; 2006 Feb; 67(2):408-9. PubMed ID: 16461098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.